<unk>  causes arterial/arteriolar vasodilation leading to a decrease in blood pressure by activating peripheral D1 receptors. It decreases afterload and also promotes sodium excretion via specific dopamine receptors along the nephron. The renal effect of<unk>  and dopamine may involve physiological antagonism of the renin-angiotensin system in the kidney. In contrast to dopamine,<unk>  is a selective D1 receptor agonist with no effect on beta adrenoceptors, although there is evidence that it may have some alpha-1 and alpha-2 adrenoceptor antagonist activity. D1 receptor stimulation activates adenylyl cyclase and raises intracellular cyclic AMP, resulting in vasodilation of most arterial beds, including renal, mesenteric, and coronary arteries. to cause a reduction in systemic vascular resistance.<unk>  has a rapid onset of action (4 minutes) and short duration of action (< 10 minutes) and a linear dose–response relationship at usual clinical doses.
Fenoldopam
Alvimopan
Nefopam
Bethanechol
Tofisopam
Ethylnorepinephrine
Avacopan
Noribogaine